Key result
Review evaluates the generalizability, cost-effectiveness, and clinical implications of the SPRINT intensive SBP target.
Why the study?
Does an intensive systolic blood pressure treatment target (<120 mm Hg) reduce cardiovascular morbidity and mortality in high-risk hypertensive patients compared to a standard target (<140 mm Hg)?
Does an intensive systolic blood pressure treatment target (<120 mm Hg) reduce cardiovascular morbidity and mortality in high-risk hypertensive patients compared to a standard target (<140 mm Hg)?
This review highlights the significant impact of the SPRINT trial on hypertension management while discussing remaining challenges regarding generalizability, feasibility, and cost-effectiveness for future clinical practice.
SPRINT's <120 mm Hg target requires individualized application amid feasibility concerns; leaves open optimal strategies for cost-effective, generalizable implementation.
The Systolic Blood Pressure Intervention Trial is the first large prospective randomized controlled trial to demonstrate the benefit of an intensive systolic blood pressure (SBP) treatment target (<120 mm Hg) compared to a standard target (<140 mm Hg) in reducing cardiovascular morbidity and mortality and all-cause mortality in high-risk hypertensive patients. The impact of SPRINT on hypertension treatment has been large, but major questions remain about the feasibility of achieving the SPRINT intensive SBP target in routine practice, the generalizability of the SPRINT findings to hypertensive populations that were excluded from the trial, and the cost effectiveness of adopting the SPRINT intensive treatment goal. In this review, we discuss the generalizability of SPRINT data to the general population of adults with hypertension and with various comorbidities, the cost effectiveness of intensive SBP-lowering therapy, and the implications of SPRINT for future hypertension guideline development and clinical practice.
No takes yet. Share an insight, caveat, or question.
Ghazi et al. (2018) conducted a review in Hypertension. Intensive systolic blood pressure treatment target (<120 mm Hg) vs. Standard target (<140 mm Hg) was evaluated on Cardiovascular morbidity and mortality and all-cause mortality. This review discusses the generalizability, cost-effectiveness, and clinical implications of the SPRINT trial's intensive systolic blood pressure target (<120 mm Hg) for hypertension management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: